CDP-choline is not protective in the SOD1-G93A mouse model of ALS

References

• Rothstein JD. Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis. Clin Neurosci. 1995;3: 348–59.
   PubMedGoogle Scholar
• Heath PR, Shaw PJ. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve. 2002;26:438–58.
   PubMed Web of Science ®Google Scholar
• Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med. 2010;48:629–41.
   PubMed Web of Science ®Google Scholar
• Takasaki K, Uchida K, Fujikawa R, Nogami A, Nakamura K, Kawasaki C, et al. Neuroprotective effects of citidine-5-diphosphocholine on impaired spatial memory in a rat model of cerebrovascular dementia. J Pharmacol Sci. 2011;116:232–7.
   PubMed Web of Science ®Google Scholar
• Hurtado O, Cardenas A, Pradillo JM, Morales JR, Ortego F, Sobrino T, et al. A chronic treatment with CDP-choline improves functional recovery and increases neuronal plasticity after experimental stroke. Neurobiology of Disease. 2007;26:105–11.
   PubMed Web of Science ®Google Scholar
• Onal MZ, Li F, Tatlisumak T, Locke KW, Sandage BW Jr, Fisher M. Synergistic effects of citicoline and MK-801 in temporary experimental focal ischaemia in rats. Stroke. 1997;28:1060–5.
   PubMed Web of Science ®Google Scholar
• Lopez-Coviella I, Agut J, Savci V, Ortiz JA, Wurtman RJ. Evidence that 5’-cytidinediphosphocholine can affect brain phospholipid composition by increasing choline and cytidine plasma levels. J Neurochem. 1995;65:889–94.
   PubMed Web of Science ®Google Scholar
• Rao AM, Hatcher JF, Dempsey RJ. Lipid alterations in transient forebrain ischaemia: possible new mechanisms of CDP-choline neuroprotection. J Neurochem. 2000;75:2528–35.
   PubMed Web of Science ®Google Scholar
• Rao AM, Hatcher JF, Dempsey RJ. Does CDP-choline modulate phospholipase activities after transient forebrain ischaemia?Brain Research. 2001;893:268–72.
   PubMed Web of Science ®Google Scholar
• Hurtado O, Moro MA, Cardenas A, Sanchez V, Fernandez-Tome P, Leza JC, et al. Neuroprotection afforded by prior citicoline administration in experimental brain ischaemia: effects on glutamate transport. Neurobiology of Disease. 2005;18:336–45.
   PubMed Web of Science ®Google Scholar
• Spreux-Varoquaux O, Bensimon G, Lacomblez L, Salachas F, Pradat PF, Le Forestier N, et al. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. Journal of the Neurological Sciences. 2002;193:73–8.
   PubMed Web of Science ®Google Scholar
• Trotti D, Rolfs A, Danbolt NC, Brown RH Jr, Hediger MA. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nature Neuroscience. 1999;2:427–33.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. The New England Journal of Medicine. 1994;330:585–91.
   PubMed Web of Science ®Google Scholar
• Clark W, Gunion-Rinker L, Lessov N, Hazel K. Citicoline treatment for experimental intracerebral haemorrhage in mice. Stroke. 1998;29:2136–40.
   PubMed Web of Science ®Google Scholar
• Cakir E, Usul H, Peksoylu B, Sayin OC, Alver A, Topbas M, et al. Effects of citicoline on experimental spinal cord injury. J Clin Neurosci. 2005;12:923–6.
   PubMed Web of Science ®Google Scholar
• Yucel N, Cayli SR, Ates O, Karadag N, Firat S, Turkoz Y. Evaluation of the neuroprotective effects of citicoline after experimental spinal cord injury: improved behavioural and neuroanatomical recovery. Neurochem Res. 2006;31: 767–75.
   PubMed Web of Science ®Google Scholar
• Alvarez XA, Mouzo R, Pichel V, Perez P, Laredo M, Fernandez-Novoa L, et al. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer’s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol. 1999;21:633–44.
   PubMedGoogle Scholar
• Matyja E, Taraszewska A, Naganska E, Grieb P, Rafalowska J. CDP-choline protects motor neurons against apoptotic changes in a model of chronic glutamate excitotoxicity in vitro. Folia Neuropathol. 2008;46:139–48.
   PubMed Web of Science ®Google Scholar
• Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science (New York, NY). 1994;264:1772–5.
   Google Scholar
• Sahin S, Alkan T, Temel SG, Tureyen K, Tolunay S, Korfali E. Effects of citicoline used alone and in combination with mild hypothermia on apoptosis induced by focal cerebral ischaemia in rats. J Clin Neurosci. 2010;17:227–31.
   PubMed Web of Science ®Google Scholar
• Krupinski J, Slevin M, Badimon L. Citicoline inhibits MAP kinase signalling pathways after focal cerebral ischaemia. Neurochem Res. 2005;30:1067–73.
   PubMed Web of Science ®Google Scholar
• Barrachina M, Dominguez I, Ambrosio S, Secades J, Lozano R, Ferrer I. Neuroprotective effect of citicoline in 6-hydroxydopamine-lesioned rats and in 6-hydroxydopamine- treated SH-SY5Y human neuroblastoma cells. Journal of the Neurological Sciences. 2003;215:105–10.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Kang JS, Kim YI. Citicoline protects against cognitive impairment in a rat model of chronic cerebral hypoperfusion. J Clin Neurol. 2009;5:33–8.
   PubMed Web of Science ®Google Scholar
• Galletti P, de Rosa M, Nappi MA, Pontoni G, del Piano L, Salluzzo A, et al. Transport and metabolism of double- labelled CDP-choline in mammalian tissues. Biochem Pharmacol. 1985;34:4121–30.
   PubMed Web of Science ®Google Scholar
• Romero A, Serratosa J, Sacristan A, Ortiz JA. High- resolution autoradiography in mouse brain and cerebellum 10 days after radiolabelled CDP-choline administration. Arzneimittelforschung. 1983;33:1058–60.
   PubMed Web of Science ®Google Scholar
• Romero A, Serratosa J, Sacristan A, Ortiz JA. Low- resolution autoradiography in rat brain after administering labelled CDP-choline. Arzneimittelforschung. 1983; 33:1054–6.
   PubMed Web of Science ®Google Scholar
• Aguilar J, Gimenez R, Bachs O, Enrich C, Agut J. Cerebral subcellular distribution of CDP-choline and/or its metabolites after oral administration of methyl-14C CDP-choline. Arzneimittelforschung. 1983;33:1051–3.
   PubMed Web of Science ®Google Scholar
• Knippenberg S, Thau N, Dengler R, Petri S. Significance of behavioural tests in a transgenic mouse model of amyotrophic lateral sclerosis (ALS). Behav Brain Res. 2010;213:82–7.
   PubMed Web of Science ®Google Scholar
• Vercelli A, Mereuta OM, Garbossa D, Muraca G, Mareschi K, Rustichelli D, et al. Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. Neurobiology of Disease. 2008;31:395–405.
   PubMed Web of Science ®Google Scholar
• Klapdor K, Dulfer BG, Hammann A, van der Staay FJ. A low-cost method to analyse footprint patterns. Journal of Neuroscience Methods. 1997;75:49–54.
   PubMed Web of Science ®Google Scholar
• Chen L, Lund PK, Burgess SB, Rudisch BE, McIlwain DL. Growth hormone, insulin-like growth factor I, and motor neuron size. J Neurobiol. 1997;32:202–12.
   PubMedGoogle Scholar
• Aslan E, Kocaeli H, Bekar A, Tolunay S, Ulus IH. CDP-choline and its endogenous metabolites, cytidine and choline, promote nerve regeneration and improve the functional recovery of injured rat sciatic nerves. Neurol Res. 2011; 33:766–73.
   PubMed Web of Science ®Google Scholar
• Turkkan A, Alkan T, Goren B, Kocaeli H, Akar E, Korfali E. Citicoline and post-conditioning provides neuroprotection in a rat model of ischaemic spinal cord injury. Acta Neurochir (Wien). 2010;152:1033–42.
   PubMed Web of Science ®Google Scholar
• Mievis S, Levivier M, Vassart G, Brotchi J, Ledent C, Blum D. Citicoline is not protective in experimental models of Huntington’s disease. Neurobiology of Aging. 2007;28:1944–6.
   PubMed Web of Science ®Google Scholar
• Garbuzova-Davis S, Saporta S, Haller E, Kolomey I, Bennett SP, Potter H, et al. Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modelling ALS. PLoS ONE. 2007;2:e1205.
   PubMed Web of Science ®Google Scholar
• Zhong Z, Deane R, Ali Z, Parisi M, Shapovalov Y, O’Banion MK, et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nature Neuroscience. 2008;11:420–2.
   PubMed Web of Science ®Google Scholar
• Crespo D, Megias M, Fernandez-Viadero C, Verduga R. Chronic treatment with a precursor of cellular phosphatidylcholine ameliorates morphological and behavioural effects of aging in the mouse (correction of rat) hippocampus. Annals of the New York Academy of Sciences. 2004;1019:41–3.
   PubMed Web of Science ®Google Scholar
• Petkov VD, Kehayov RA, Mosharrof AH, Petkov VV, Getova D, Lazarova MB, et al. Effects of cytidine diphosphate choline on rats with memory deficits. Arzneimittelforschung. 1993;43:822–8.
   PubMed Web of Science ®Google Scholar
• Drago F, Mauceri F, Nardo L, Valerio C, Genazzani AA, Grassi M. Effects of cytidine-diphosphocholine on acetylcholine-mediated behaviours in the rat. Brain Res Bull. 1993;31:485–9.
   PubMed Web of Science ®Google Scholar
• Conant R, Schauss AG. Therapeutic applications of citicoline for stroke and cognitive dysfunction in the elderly: a review of the literature. Altern Med Rev. 2004;9: 17–31.
   PubMedGoogle Scholar
• Agut J, Lopez GCI, Ortiz JA, Wurtman RJ. Oral cytidine 5’-diphosphate choline administration to rats increases brain phospholipid levels. Annals of the New York Academy of Sciences. 1993;695:318–20.
   PubMed Web of Science ®Google Scholar
• Weiss GB. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sciences. 1995;56:637–60.
   PubMed Web of Science ®Google Scholar
• Rao AM, Hatcher JF, Dempsey RJ. CDP-choline: neuroprotection in transient forebrain ischaemia of gerbils. Journal of Neuroscience Research. 1999;58:697–705.
   PubMed Web of Science ®Google Scholar
• Agut J, Font E, Sacristan A, Ortiz JA. Radioactivity incorporation into different cerebral phospholipids after oral administration of 14C methyl CDP-choline. Arzneimittelforschung. 1983;33:1048–50.
   PubMed Web of Science ®Google Scholar
• Dinsdale JR, Griffiths GK, Rowlands C, Castello J, Ortiz JA, Maddock J, et al. Pharmacokinetics of 14C CDP-choline. Arzneimittelforschung. 1983;33:1066–70.
   PubMed Web of Science ®Google Scholar
• Garcia-Cobos R, Frank-Garcia A, Gutierrez-Fernandez M, Diez-Tejedor E. Citicoline, use in cognitive decline: vascular and degenerative. Journal of the Neurological Sciences. 2010;299:188–92.
   PubMed Web of Science ®Google Scholar
• Cho HJ, Kim YJ. Efficacy and safety of oral citicoline in acute ischaemic stroke: drug surveillance study in 4191 cases. Methods Find Exp Clin Pharmacol. 2009;31:171–6.
   PubMedGoogle Scholar
• Citicoline.Monograph. Altern Med Rev. 2008;13:50–7.
   PubMedGoogle Scholar
• Clement AM, Nguyen MD, Roberts EA, Garcia ML, Boillee S, Rule M, et al. Wild-type non-neuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science (New York, NY). 2003;302:113–7.
   Google Scholar
• Boillee S, Vandevelde C, Cleveland DW. ALS: a disease of motor neurons and their non-neuronal neighbors. Neuron. 2006;52:39–59.
   PubMed Web of Science ®Google Scholar
• Diaz-Amarilla P, Olivera-Bravo S, Trias E, Cragnolini A, Martinez-Palma L, Cassina P, et al. Phenotypically aberrant astrocytes that promote motor neuron damage in a model of inherited amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America. 2011;108:18126–31.
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Bruijn L, Conwit R, Beal F, O’Neill G, Fagan SC, et al. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology. 2006;67:20–7.
   PubMed Web of Science ®Google Scholar
• Wang R, Zhang D. Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. The European Journal of Neuroscience. 2005;22:2376–80.
   PubMed Web of Science ®Google Scholar
• Choi JK, Kustermann E, Dedeoglu A, Jenkins BG. Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation. The European Journal of Neuroscience. 2009;30: 2143–50.
   PubMed Web of Science ®Google Scholar
• Kiaei M, Kipiani K, Petri S, Choi DK, Chen J, Calingasan NY, et al. Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem. 2005;93:403–11.
   PubMed Web of Science ®Google Scholar
• Petri S, Kiaei M, Kipiani K, Chen J, Calingasan NY, Crow JP, et al. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiology of Disease. 2006;22:40–9.
   PubMed Web of Science ®Google Scholar
• Pascuzzi RM, Shefner J, Chappell AS, Bjerke JS, Tamura R, Chaudhry V, et al. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:266–71.
   PubMed Web of Science ®Google Scholar
• de Carvalho M, Pinto S, Costa J, Evangelista T, Ohana B, Pinto A. A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:456–60.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Annals of Neurology. 2006;60:22–31.
   PubMed Web of Science ®Google Scholar